Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XH001 and mFOLFIRINOX in High-risk Recurrent Solid Tumors After Radical Surgery
NCT07594964Phase 1Recruiting
- Sponsor
- neoX Biotech
- Start
- Aug 2025
- Primary completion
- Oct 2029
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PGV002 in biliary cancer, pancreatic ductal adenocarcinoma (PDAC), hepatocellular carcinoma (HCC) and 1 more, sponsored by neoX Biotech. Primary endpoints: Adverse Event up to 36 months, Dose-Limiting Toxicity up to 4 weeks and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
PGV002
03
Conditions
biliary cancerpancreatic ductal adenocarcinoma (PDAC)hepatocellular carcinoma (HCC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT07594964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594964.